Refreshed 1 min ago
STAT+: Pharmalittle: We’re reading about Sanofi eyeing Insmed, AI speeding drug development, and more
Why it’s here: This is a multi-story pharma newsletter digest; however it includes policy-relevant items (House China committee probe of pharma trial sites in Xinjiang and FDA action against J&J) in the biotechnology area, so it is partially relevant but the roundup format is a rejection factor.
Trace across the boardItem
2d agoSTATSTAT+: Pharmalittle: We’re reading about Sanofi eyeing Insmed, AI speeding drug development, and moreThis STAT Pharmalittle roundup notes that major pharmaceutical firms are using AI for molecule design and early-stage work, and that several large drugmakers pledged to the House China committee to avoid new Xinjiang and military-affiliated trial sites. Biotech17 linked
Coverage
1 outlets · first seen 2d agoConnected
6 links- NewsSTAT+: Big drugmakers tell House committee they will halt clinical trials at some hospitals in ChinaBoth involve Eli Lilly, Merck, AbbVie
- HillHearings to examine caregivers and AI, focusing on opportunities, challenges, and threats.Both involve artificial intelligence
- NewsThe AI boom is forecast to increase data center emissions by 70% by 2030Both involve artificial intelligence
- NewsPull out 'weeks' of cash: Democratic defector Andrew Yang warns Americans to brace for 18 months of rolling outagesBoth involve artificial intelligence
- NewsUS: Protesters demand human control over AI after Anthropic's IPOBoth involve artificial intelligence
- NewsSTAT+: Lawmakers want U.S. biotech to outcompete ChinaBoth involve Merck
About
- House China committee
- Merck
- artificial intelligence